SCHEMBL30175552

SCHEMBL30175552

CC(C)(C)OC(=O)Nc1ccc(Cc2ccc(Cl)cc2F)nn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.43
HTT P42858 3/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPT P10636 2/20 0.43
GAA P10253 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PTGER1 P34995 2/20 0.41
CYP2C9 P11712 1/20 0.40
GLS O94925 6/20 0.40
RIPK3 Q9Y572 1/20 0.40
IDO1 P14902 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
TP53 P04637 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GLA P06280 1/20 0.38
XBP1 P17861 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25113458 1.00 SMN1; SMN2 (0.43) SMN1; SMN2HTTKDM4EMAPTGAA
SCHEMBL29353767 0.81 KDM4E (0.46) KDM4EPTGER1CYP2C9GLS
SCHEMBL21394859 0.81 KDM4E (0.46) KDM4EPTGER1CYP2C9GLS
SCHEMBL30672289 0.79 GLS (0.42) GLS
SCHEMBL26822836 0.79 GLS (0.42) GLS
SCHEMBL30672258 0.75 GLS (0.43) GLS
SCHEMBL26822131 0.75 GLS (0.43) GLS
SCHEMBL24824441 0.75 GLS (0.43) GLS
SCHEMBL13874581 0.74 PTGER1 (0.64) PTGER1CYP2C9
SCHEMBL25082075 0.74 GLS (0.54) GLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115606-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2025-04-10 US disclosed
US-12221442-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2025-02-11 US disclosed
US-20240246962-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2024-07-25 US disclosed
US-11926626-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2024-03-12 US disclosed
US-20230107793-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-04-06 US disclosed
US-20230071840-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246962-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR SMN1; SMN2 1232/4885HTT 819/4885KDM4E 3289/4885
US-12221442-B2 Heterocyclic GLP-1 agonists GLP1R, GIPR, GCGR SMN1; SMN2 1232/4885HTT 819/4885KDM4E 3289/4885
US-20250115606-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR SMN1; SMN2 1232/4885HTT 819/4885KDM4E 3289/4885
US-20230071840-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR SMN1; SMN2 1232/4885HTT 819/4885KDM4E 3289/4885
US-11926626-B2 Heterocyclic GLP-1 agonists GLP1R, GIPR, GCGR SMN1; SMN2 1232/4885HTT 819/4885KDM4E 3289/4885
US-20230107793-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR SMN1; SMN2 1232/4885HTT 819/4885KDM4E 3289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.